Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4633014 | 0.96 | FFAR3 (0.41) | — | |
| SCHEMBL1332396 | 0.96 | — | — | |
| SCHEMBL9342808 | 0.96 | FFAR3 (0.41) | — | |
| SCHEMBL3851900 | 0.96 | — | — | |
| SCHEMBL7064730 | 0.96 | CA4 (0.47) | — | |
| Pyruvate SCHEMBL31434671 | 0.83 | CA4 (0.50) | — | |
| Propionic Acid SCHEMBL106190 | 0.80 | — | — | |
| Propionic Acid SCHEMBL4896693 | 0.80 | FFAR3 (0.53) | — | |
| Propionic Acid SCHEMBL29493216 | 0.80 | FFAR3 (0.53) | — | |
| SCHEMBL108375 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1830828-A4 | USE OF METHYL PYRUVATE TO INCREASE CELLULAR ENERGY PRODUCTION DOWNSTREAM OF GLYCOLYSIS | ANTOSH & MEDURI HOLDING CORP (US) | 2008-07-02 | — | — | EP | claimed |
| EP-1781108-A4 | USE OF METHYL PYRUVATE FOR THE PURPOSE OF INCREASING MUSCLE ENERGY PRODUCTION | ANTOSH STANLEY C (US) | 2008-06-04 | — | — | EP | claimed |
| EP-1830828-A2 | USE OF METHYL PYRUVATE TO INCREASE CELLULAR ENERGY PRODUCTION DOWNSTREAM OF GLYCOLYSIS | Antosh & Meduri Holding Corporation (US) | 2007-09-12 | — | — | EP | claimed |
| EP-1796460-A2 | USE OF METHYL PYRUVATE OR METHYL PYRUVIC ACID FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM AND FOR PROTECTING A HUMAN CENTRAL NERVOUS SYSTEM AGAINST NEURONAL DEGENERATION CAUSED BY DEFECTIVE INTRACELLULAR ENERGY PRODUCTION | Antosh, Stanley C. (US) | 2007-06-20 | — | — | EP | claimed |
| EP-1781108-A2 | USE OF METHYL PYRUVATE FOR THE PURPOSE OF INCREASING MUSCLE ENERGY PRODUCTION | Antosh, Stanley C. (US) | 2007-05-09 | — | — | EP | claimed |
| WO-2006055764-A2 | USE OF METHYL PYRUVATE TO INCREASE CELLULAR ENERGY PRODUCTION DOWNSTREAM OF GLYCOLYSIS | ANTOSH STANLEY C (US) | 2006-05-26 | — | — | WO | claimed |
| US-20060111442-A1 | Use of methyl pyruvate to increase cellular energy production downstream of glycolysis for the PARP-1 ablation of HIV without necrotic cell death caused by continuous, chronic PARP-1 activation through the concomitant depletion of ATP and NAD. | Antosh, Mr. Stanley (US) | 2006-05-25 | — | — | US | claimed |
| WO-2006028948-A2 | USE OF METHYL PYRUVATE OR METHYL PYRUVIC ACID FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM AND FOR PROTECTING A HUMAN CENTRAL NERVOUS SYSTEM AGAINST NEURONAL DEGENERATION CAUSED BY DEFECTIVE INTRACELLULAR ENERGY PRODUCTION | ANTOSH STANLEY C (US) | 2006-03-16 | — | — | WO | claimed |
| US-20060052448-A1 | Use of methyl pyruvate or methyl pyruvic acid for the treatment of diseases of the nervous system and for protecting a human central nervous system against neuronal degeneration caused by defective intracellular energy production. | Antosh, Mr. Stanley (US) | 2006-03-09 | — | — | US | claimed |
| WO-2006017590-A2 | USE OF METHYL PYRUVATE FOR THE PURPOSE OF REDUCING WEIGHT GAIN IN MAMMALS | ANTOSH STANLEY C (US) | 2006-02-16 | — | — | WO | claimed |
| WO-2006015232-A2 | USE OF METHYL PYRUVATE FOR THE PURPOSE OF INCREASING MUSCLE ENERGY PRODUCTION | ANTOSH STANLEY C (US) | 2006-02-09 | — | — | WO | claimed |
| US-20060025475-A1 | Use of methyl pyruvate for the purpose of increasing muscle energy production. | Antosh, Stanley (US) | 2006-02-02 | — | — | US | claimed |
| US-20060025476-A1 | Use of methyl pyruvate for the purpose of reducing weight gain in mammals. | Antosh, Stanley (US) | 2006-02-02 | — | — | US | claimed |
| US-7683092-B2 | Crystalline forms of antidiabetic compounds | MERCK SHARP & DOHME CORP. (US) | 2010-03-23 | — | — | US | disclosed |
| EP-1858844-A4 | NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS | MERCK & CO INC (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20080221198-A1 | Novel Crystalline Forms of Antidiabetic Compounds | MERCK SHARP & DOHME CORP. | 2008-09-11 | — | — | US | disclosed |
| US-20060025475-A1 | Use of methyl pyruvate for the purpose of increasing muscle energy production. | Antosh, Stanley (US) | 2006-02-02 | — | — | US | disclosed |
| EP-0386476-B1 | Process for producing L-alanine | MITSUBISHI PETROCHEMICAL CO (JP) | 1994-07-13 | — | — | EP | disclosed |
| US-5116743-A | Fumaric acid and ammonia, heat treatment of bacteria | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1992-05-26 | — | — | US | disclosed |
| EP-0386476-A1 | Process for producing L-alanine | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1990-09-12 | — | — | EP | disclosed |